STOCK TITAN

Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Anteris Technologies Global (AVR) reported one-year DurAVR heart valve results in patients with severe aortic valve narrowing and small valve openings. Among 100 patients pooled from EMBARK and early feasibility studies, 1% were hospitalized for heart failure and no valve-related deaths were reported through one year. Mean pressure across the valve fell from 48.1 to 8.9 mmHg, with no moderate or severe leakage around the valve. The share of patients with no or mild symptoms rose from 39% to 96%.

At one year, all-cause mortality was 6%, stroke occurred in 3% and 9% received a new permanent pacemaker. At 30 days, 97% were free from moderate or severe mismatch between the valve opening and body size. The pivotal PARADIGM trial is enrolling in the United States and Europe to compare DurAVR with commercially available transcatheter valves.

Loading...
Loading translation...

Positive

  • Minor pointHeart failure hospitalization was 1% at one year in the 100-patient DurAVR cohort
  • Minor pointValve-related deaths were not reported through one year
  • Minor pointMean pressure gradient fell from 48.1 ± 17.0 mmHg at baseline to 8.9 ± 4.3 mmHg at one year
  • Minor pointMean effective valve opening area rose from 0.8 ± 0.2 cm² at baseline to 2.2 ± 0.9 cm² at one year
  • Minor pointModerate or severe leakage around the valve was not observed through one year
6 minor points
  • Minor pointModerate or severe deterioration in valve function was not observed at one year
  • Minor pointPatients with no or mild symptoms increased from 39% at baseline to 96% at one year
  • Minor pointSymptom improvement was reported in 81% of patients at one year
  • Minor pointValve fit was free from moderate or severe mismatch in 97% of patients at 30 days
  • Minor pointLeft ventricular mass fell 24% at one year in a 64-patient cardiac MRI substudy
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pivotal PARADIGM trial is enrolling in the United States and Europe, with approximately 1,000 patients planned for its randomized cohort

Negative

  • Minor pointAll-cause mortality was 6% at one year
  • Minor pointStroke occurred in 3% of patients at one year
  • Minor pointNew permanent pacemaker implantation occurred in 9% of patients at one year

News Explained

Commercial use remains unavailable; the roughly one-thousand-patient randomized trial will test a one-year clinical composite.

At the November 22, 2026 presentation, Anteris reported a 24% one-year regression in left-ventricular mass in a cardiac magnetic resonance substudy of 64 patients; DurAVR remains investigational and unavailable for commercial sale.

The next evidence checkpoint is the actively enrolling PARADIGM trial, a randomized comparison planned for about 1,000 patients assigned 1:1 to DurAVR or approved commercial valves.

The trial will test non-inferiority on a one-year composite of all-cause mortality, all stroke, and cardiovascular hospitalization.

Key Figures

Patients: 100 patients Heart failure hospitalization: 1% Mean pressure gradient: 48.1 ± 17.0 to 8.9 ± 4.3 mmHg +5 more
Patients
100 patients
Pooled cohort with severe aortic stenosis and small aortic annuli
Heart failure hospitalization
1%
At 1 year
Mean pressure gradient
48.1 ± 17.0 to 8.9 ± 4.3 mmHg
Baseline to 1 year
Mean effective orifice area
0.8 ± 0.2 to 2.2 ± 0.9 cm2
Baseline to 1 year
Freedom from moderate or severe PPM
97%
At 30 days
NYHA class I/II
39% to 96%
Baseline to 1 year
All-cause mortality
6%
At 1 year
Left ventricular mass regression
24%
At 1 year in a cardiac magnetic resonance substudy (n = 64)

Key Terms

paravalvular leak, prosthesis-patient mismatch, effective orifice area, nyha, +2 more
6 terms
paravalvular leak medical
"no moderate or severe paravalvular leak (PVL) observed"
A paravalvular leak is blood flow that escapes around, rather than through, a surgically implanted or transcatheter heart valve because the valve’s sealing interface against the patient’s native tissue is incomplete or has separated. It produces varying degrees of regurgitation and can cause symptoms or complications such as heart failure or red blood cell destruction (hemolysis); clinicians diagnose and grade it by imaging (usually echocardiography) and sometimes treat it with catheter-based closure or repeat surgery depending on severity.
prosthesis-patient mismatch medical
"prosthesis-patient mismatch* (PPM)"
A prosthesis‑patient mismatch occurs when an implanted prosthetic heart valve has an effective opening that is too small for the patient's body size, producing higher-than-expected blood‑flow resistance across the valve. Clinically it is assessed by the valve’s effective orifice area (EOA) indexed to the patient’s body surface area (EOA/BSA); lower indexed EOA values indicate a greater mismatch and correlate with higher transvalvular gradients and reduced valve hemodynamic performance. Valve label size alone does not define mismatch, because EOA varies by valve design and how the valve functions in a given patient; assessment uses echocardiography or measured EOA values and accounts for body size to determine whether a mismatch is present and how severe it is.
effective orifice area medical
"mean effective orifice area (EOA) of 2.2 cm2"
Effective orifice area (EOA) is the functional cross‑sectional area through which blood flows across a heart valve during ejection, measured under actual flow conditions rather than by the valve’s physical opening. Clinically it is estimated from Doppler echocardiography using the continuity equation (relating flow upstream and through the valve) and is reported in square centimeters; because it reflects flow contraction and velocity, EOA is typically smaller than the anatomical or geometric opening and changes with cardiac output and measurement technique.
nyha medical
"New York Heart Association (NYHA) class I/II"
A four-level scale doctors use to describe how much heart failure limits a person’s everyday activities, ranging from no symptoms during ordinary activity to symptoms at rest. Investors pay attention because changes in NYHA class are common clinical trial and regulatory endpoints that show whether a medicine or device meaningfully improves patients’ daily function; think of it as a simple fuel gauge for how well a treatment restores a patient’s energy and capability.
sts-prom medical
"the mean STS-PROM score was 4.7 ± 4.0%"
STS-PROM is a risk score from the Society of Thoracic Surgeons that estimates a patient’s probability of dying within 30 days after cardiac surgery. The score is calculated by applying the STS risk model to a patient’s clinical and demographic characteristics and is used to compare expected surgical risk across patients, procedures, hospitals, and clinical studies. It is a statistical prediction based on model inputs, not a certainty for any individual patient, and its accuracy depends on the model version and the data used to calculate it.
tavr medical
"transcatheter aortic valve replacement (TAVR)"
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces a failing aortic heart valve by delivering a new valve through a blood vessel instead of opening the chest. It matters to investors because TAVR expands who can be treated, shortens hospital stays and recovery, and shapes revenue, regulatory risk and reimbursement for medical device makers, hospitals and insurers—similar to how a popular new product can reshape an industry’s market and costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Late-breaking 1-year data in 100 patients presented at PCR London Valves 2026: No moderate or severe paravalvular leak, 96% in NYHA class I/II and 97% free from moderate or severe prosthesis-patient mismatch at 30 days

MINNEAPOLIS and BRISBANE, Nov. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced 1-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli (annulus area 404 ± 37 mm2), the anatomy in which transcatheter valves most often leave patients with elevated gradients and prosthesis-patient mismatch* (PPM).

At 1 year, 1% of patients had been hospitalized for heart failure. DurAVR THV maintained a mean pressure gradient of 8.9 mmHg and a mean effective orifice area (EOA) of 2.2 cm2, with no moderate or severe paravalvular leak (PVL) observed and no valve-related mortality reported. At 30 days, 97% of patients were free from moderate or severe PPM. Symptoms improved substantially: the proportion of patients who achieved New York Heart Association (NYHA) class I/II rose from 39% at baseline to 96% at 1 year.

These results were achieved in a symptomatic and clinically complex population. At baseline, 61% of patients were in NYHA class III/IV, the mean STS-PROM score was 4.7 ± 4.0%, and the cohort included heavy calcification and bicuspid anatomy (9%). Patients were pooled from the EMBARK and early feasibility studies (EFS) conducted in the United States and Europe; previously, 30-day data from this cohort were presented at PCR London Valves 2025.

The late-breaking abstract, titled “One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli,” was presented by Rishi Puri, MD, PhD, of Cleveland Clinic, during the TAVI Hotline – Part 1 session at PCR London Valves on Sunday, November 22, 2026.

1 Year Results Highlights

  • Heart failure hospitalization: 1% at 1 year compares favorably to mid-to-high single-digit rates reported in contemporary clinical trials with currently marketed products.1,2
  • Hemodynamics: Mean pressure gradient fell from 48.1 ± 17.0 mmHg at baseline to 8.9 ± 4.3 mmHg at 1 year, and mean EOA increased from 0.8 ± 0.2 cm2 to 2.2 ± 0.9 cm2. These results were similar to those reported at 30 days in 2025.
  • Hemodynamic Valve Deterioration: No moderate or severe hemodynamic valve deterioration was observed at 1 year.
  • Valve performance: No moderate or severe PVL was observed and no valve-related deaths were reported through 1 year.
  • Symptoms: Patients in NYHA class I/II increased from 39% at baseline to 96% at 1 year, and 81% of patients experienced symptom improvement.
  • Clinical events at 1 year: All-cause mortality 6% (2 CV mortalities; 2 non-cardiac infections; 1 cancer; 1 car accident), stroke 3% and new permanent pacemaker implantation 9%.
  • Cardiac remodeling: In a cardiac magnetic resonance (CMR) substudy (n = 64), left ventricular (LV) mass, a marker of modifying the underlying disease, regressed by 24% at 1 year. LV mass in the patients evaluated was similar to that reported in matched controls without aortic valve disease3. These findings are consistent with sustained unloading of the left ventricle.

“Small aortic annuli are where we most often see elevated gradients and mismatch after TAVR, and these patients are disproportionately women. In this symptomatic cohort, DurAVR delivered single-digit gradients, no moderate or greater paravalvular leak and 97% freedom from moderate or severe mismatch at 30 days. While cross-trial comparisons should be interpreted with caution, what stands out to me is heart failure hospitalization of just 1% at one year. These patients had a mean STS score of 4.7%, and most were in NYHA class III or IV, yet 1% is well below the hospitalization rates reported in contemporary clinical trials with currently marketed products. These are encouraging results, and the randomized PARADIGM trial is the right next test,” said Rishi Puri, MD, PhD, Interventional Cardiologist, Cleveland Clinic, Cleveland, Ohio, United States.

“Small annuli are the hardest test in TAVR, and these patients were symptomatic, with 61% in NYHA class III or IV at baseline. At one year, heart failure hospitalization was just 1%, a fraction of the rate typically observed after valve replacement. Heart failure admissions are the event patients feel most, health systems pay for most and that most closely predicts mortality. The cardiac MRI data show why DurAVR is different: with single-digit gradients and no moderate or severe paravalvular leak, left ventricular mass regressed by 24%, which tells us the heart is unloading and beginning to remodel. We believe DurAVR's biomimetic design and its potential to restore more physiologic blood flow may contribute to improved cardiac remodeling. These findings are consistent with that hypothesis, and PARADIGM is designed to test DurAVR head-to-head against today’s commercial valves. These results give us strong conviction going into the pivotal trial,” said Chris Meduri, MD, MPH, Chief Medical Officer of Anteris.

“Reducing heart failure hospitalization is among the most consequential events after aortic valve replacement, due to its proven correlation with CV mortality. In a pooled analysis of more than 3,400 patients treated with TAVR or surgical aortic valve replacement in the PARTNER trials, the 1-year heart failure hospitalization rate was 6.7%, and these hospitalizations were associated with increased mortality.1 In the randomized SMART trial of small-annulus patients at lower predicted risk (mean STS-PROM 3.3%), 1-year heart failure hospitalization was 4.1% with the Evolut valve and 3.5% with the SAPIEN valve.2 Against this backdrop, our current dataset gives us great confidence for the ongoing pivotal PARADIGM study where cardiovascular hospitalization is also a component of the primary endpoint,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.

The DurAVR THV is being studied in the pivotal PARADIGM Trial (ClinicalTrials.gov ID NCT07194265), a randomized, head-to-head comparison against commercially available TAVR valves that is actively enrolling patients across the United States and Europe.

1Huded CP, et al. Circ Cardiovasc Interv. 2022;15(12):e012195.

2Herrmann HC, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. 2024;390:1959-1971. Component rates (Kaplan-Meier) from SMART results posted at ClinicalTrials.gov, NCT04722250.

3Garg P, et al. European Heart Journal, Valvular & Structural Disease; 2026.

*Prosthesis-patient mismatch (PPM) occurs when an implanted valve’s effective opening is too small for the patient’s body size, resulting in higher-than-expected gradients. PPM is common after transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and has been associated with reduced long-term survival after surgical aortic valve replacement (SAVR).

About the PARADIGM Trial

The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs).

This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort' with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure.

For further information, please refer to ClinicalTrials.gov NCT07194265.

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR® Delivery System.

DurAVR THV is intended for INVESTIGATIONAL USE ONLY. Not available for commercial use or sale worldwide. CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, that were filed with the Securities and Exchange Commission and ASX. Early or pooled clinical results, including those described in this announcement, may not be predictive of future results, including results in the PARADIGM pivotal trial. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

For more information:

Global Investor RelationsInvestor Relations (US)
investors@anteristech.commchatterjee@bplifescience.com
Debbie OrmsbyMalini Chatterjee, Ph.D.
Anteris Technologies Global Corp.Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200+1 917 330 4269


Websitewww.anteristech.com
X@AnterisTech
LinkedInhttps://www.linkedin.com/company/anteristech



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Anteris test in the DurAVR PARADIGM trial?

PARADIGM will test whether DurAVR is not unacceptably worse than commercially available transcatheter valves on a combined measure of death from any cause, any stroke and cardiovascular hospitalization one year after the procedure. The trial plans to assign approximately 1,000 patients in its randomized cohort equally to the two groups.

What did Anteris find in the DurAVR cardiac MRI substudy?

In the 64-patient cardiac MRI substudy, left ventricular mass decreased 24% at one year. Left ventricular mass in the patients evaluated was similar to that reported in matched people without aortic valve disease.

Keep reading